Zai Lab
Lois Li is a finance professional with over a decade of experience in financial management and strategic planning across various industries. Currently serving as Senior Finance Manager at 再鼎医药 since April 2020, Lois oversees CSOP planning, distribution management, and business partnership initiatives. Previous roles include Finance Manager at TE 中国, where responsibilities encompassed global pricing strategies and margin expansion for commercial appliances, as well as FP&A Manager for Greater China & SEA in the Industrial BU, focusing on financial controlling and business partnerships. Lois's career began at Ingersoll Rand as a Senior Financial Analyst, contributing to analysis and forecasting for the AP region. Lois holds a Master's degree in Accounting from Southwestern University of Finance and Economics, completed in 2009.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.